Hoffman-Censits, J, Tsiatas, M, Chang, PMH, Kim, M, Zagouri, F, Shin, SJ, Kim, SH, Su, HYL, Arija, JAA, Maroto-Rey, JP, Antonuzzo, L, Maruzzo, M, Tambaro, R, Blais, N, Rottey, S, Gakis, G, Schneider, A, Tyroller, K, Jacob, N, Valderrama, BP. Avelumab (Ave) in combination with other anticancer agents as first-line maintenance (1LM) treatment for advanced urothelial carcinoma (aUC): Primary analysis from the JAVELIN Bladder Medley phase 2 trial.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.739. PMID:. IF:41.900(Q1/1D).

Gregorc, V, Majem, M, Lo Russo, G, Maio, M, Salvagni, S, Gutiérrez-Calderon, V, Gonzalez-Cao, M, Contreras, SS, Koumarianou, A, Bearz, A, Bernabé-Caro, R, Viteri, S, de Sanmamed, MF, Zagouri, F, Bueno, TM, Lazzari, C, Martínez-Recio, S, Giménez-Capitán, A, Zhang, Y, Shan, Y, Zhu, HQ, Zhao, CQ, Shen, HG, Wang, Y, Rosell, R. Fulzerasib plus cetuximab in first-line KRASG12C-mutated nonsmall-cell lung cancer (KROCUS): a single-arm, multicentre, phase 1b/2 trial. LANCET ONCOLOGY. 2026; 27(4)DOI:10.1016/S1470-2045(25)00764-8. PMID:41926959. IF:35.900(Q1/1D).

Garcia, AM, Rezqallah-Arón, A, Duran-Lozano, L, López-Fernández, A, Darder, E, Alfonso, R, Cartró, M, Cruellas, M, Reig-Jané, J, Roqué, A, Tuset, N, Cajal, TRY, Brunet, J, Balmaña, J. Evaluating the added value of a multifactorial model over gene-based risk estimates in breast cancer prediction for healthy carriers of pathogenic variants. EUROPEAN JOURNAL OF CANCER. 2026; 237DOI:10.1016/j.ejca.2026.116560. PMID:. IF:7.100(Q1/2D).

Villarrubia, JE, Fita, MJJ, de Liaño, AG, Cerrillomd, JM, Cruz, P, Anguera, G, Puente, J, Torras, OR, Navarro-Gorro, N, Pinto, A, Ruiz, SG, Cacho, D, Maeso, IG, González, NS, Lainez, N, Herranz, UA, Carrera-Lasfuentes, P, Climent, MA, Macías, NR, Castellano, D. Real-world data of enfortumab vedotin in patients with advanced urothelial cancer in Spain: The ENFANTS-GUARD study.. JOURNAL OF CLINICAL ONCOLOGY. 2026; 44(7_SUPPL)DOI:10.1200/JCO.2026.44.7_suppl.700. PMID:. IF:41.900(Q1/1D).